Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

The FDA has approved clinical trials for organ transplants using genetically modified pigs, starting with six patients with ...

Glatopa, a generic version of Teva’s product, was approved by the FDA this year and marketed by Sandoz. The drugs have demonstrated a 34% drop in the number of relapses compared to placebo. The FDA ...

However, it had to be used in conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the nasal spray for adults with treatment-resistant major ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Cortland, New York – Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Red 3, also known as erythrosine or FD&C Red No. 3, is a red synthetic food dye used to give certain drinks, cough syrups and foods “a bright, cherry color,” according to the FDA. The agency’s report ...

Jan 21 (Reuters) - The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's (JNJ.N), opens new tab nasal spray, Spravato, to allow it to be used as a standalone treatment ...